The “Special 301”report from the Office of the United States Trade Representative will be out later this month. The report is a scorecard of sorts by the US of its trading partners, who are graded on their performance in handling Intellectual Property Rights (IPR). The report is keenly watched by domestic industry sectors, especially the pharmaceutical industry, besides infotech and electronics, given the role of IP — patents, trademarks and copyrights. This year, too, a representation from the Indian pharmaceutical industry made its submission to the USTR, making a strong case to take India off the “Priority Watch List”. India is on this 12-member PWL list along with Canada, Russia and China, among others.